Matt Zuga

CIK: 0001790214

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (76.9%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (23.1%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ABOS

Acumen Pharmaceuticals, Inc.

Officer

ELUT

ELUTIA INC.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (13 total)

ABOS
Acumen Pharmaceuticals, Inc.
Jan 22, 2026
Sale(S)
Direct
1.7K shares at avg. $1.86$3K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 21, 2026
Sale(S)
Direct
2.5K shares at avg. $1.81$4K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 16, 2026
Award(A)
Direct
99.1K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jan 8, 2026
Sale(S)
Direct
6.9K shares at avg. $1.82$13K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 7, 2026
Sale(S)
Direct
4.1K shares at avg. $2.00$8K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 7, 2026
Sale(S)
Direct
1.7K shares at avg. $1.99$3K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 6, 2026
Sale(S)
Direct
5.1K shares at avg. $1.97$10K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 5, 2026
Sale(S)
Direct
4K shares at avg. $1.96$8K
ELUT
ELUTIA INC.
May 29, 2025
Award(A)
Stock Option (Right to Buy)
Direct
60.3K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jan 23, 2025
Sale(S)
Direct
28.9K shares at avg. $1.72$50K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 21, 2025
Sale(S)
Direct
4.4K shares at avg. $1.60$7K
ABOS
Acumen Pharmaceuticals, Inc.
Jan 6, 2025
Award(A)
Direct
66.8K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jan 3, 2025
Sale(S)
Direct
13.2K shares at avg. $1.84$24K

		Type	Shares	Price		Ownership
Jan 22, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	1,687	$1.86	$3,138	Direct
Jan 21, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	2,473	$1.81	$4,469	Direct
Jan 16, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	99,133	-	$0	Direct
Jan 8, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	6,888	$1.82	$12,513	Direct
Jan 7, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	4,105	$2.00	$8,189	Direct
Jan 7, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	1,700	$1.99	$3,377	Direct
Jan 6, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	5,100	$1.97	$10,028	Direct
Jan 5, 2026	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	4,000	$1.96	$7,842	Direct
May 29, 2025	ELUT ELUTIA INC.	Award(A) Stock Option (Right to Buy)	60,339	-	-	Direct
Jan 23, 2025	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	28,902	$1.72	$49,633	Direct
Jan 21, 2025	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	4,364	$1.60	$6,986	Direct
Jan 6, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	66,800	-	$0	Direct
Jan 3, 2025	ABOS Acumen Pharmaceuticals, Inc.	Sale(S)	13,235	$1.84	$24,367	Direct

1-13 of 13 transactions

About Zuga Matt

Zuga Matt (SEC CIK 0001790214) files insider reports with the SEC as CFO & Chief Business Officer of Acumen Pharmaceuticals, Inc. (ABOS) and Director of ELUTIA INC. (ELUT).

Signal8 holds 7 ownership filings by Zuga Matt, all Form 4s, filed between Jan 7, 2025 and Jan 23, 2026. Those filings report 13 transactions, from Jan 3, 2025 to Jan 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zuga Matt's filings is in NEWTON, MA.

Recent filings by Zuga Matt

Jan 22, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 21, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 16, 2026: Grant or award of ABOS shares (Form 4, code A).
Jan 8, 2026: Open-market sale of ABOS shares (Form 4, code S).
Jan 7, 2026: Open-market sales of ABOS shares (2 lines, Form 4, code S).

Other insiders filing for Acumen Pharmaceuticals, Inc. (ABOS)

How to read Form 4 transaction codes